The Longevity Podcast: Alzheimer's and Brain Health Research

Send us Fan Mail

A silent crisis is unfolding in plain sight: mild cognitive impairment is missed at staggering rates, even as new Alzheimer’s treatments work best in the earliest stages. We sit down with the data and the day-to-day reality of primary care to ask a harder question—how do we turn belief and capability into action under relentless time pressure?

Our journey follows the Davos Alzheimer’s Collaborative through a global field test spanning Brazil, Jamaica, Mexico, Scotland, and two U.S. sites. Teams rolled out digital cognitive assessments and, where possible, blood-based biomarkers—then adapted to local constraints to make early detection feasible. In Jamaica, a lack of Alzheimer’s biomarkers led to subsidized labs and ECGs for positive screens, catching reversible causes like thyroid issues and vitamin deficiencies. That’s implementation science in motion: tailor the tools to the clinic, not the clinic to the tools.

The results are revealing. Clinicians already valued early diagnosis, but confidence jumped nearly 10% after the rollout, especially where digital assessments and biomarkers were used together. And yet, engagement—the willingness to weave screening into daily practice—barely moved. That paradox reframes the problem. The bottleneck isn’t knowledge or motivation; it’s workflow. We explore the system fixes that actually unlock adoption: pre-visit screening, delegation to support staff, EHR order sets and templates, clear next steps after a positive screen, and protected time. We also point to a free Early Detection Blueprint built from these lessons to help leaders design pathways that fit real clinics.

If you care about aging, primary care, Alzheimer’s research, or practical health innovation, this conversation offers a grounded, hopeful path forward. Subscribe, share with a colleague who shapes clinical workflows, and leave a review with one change you’d make to boost early detection in your setting.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We trace how everyday blood pressure quietly influences the earliest Alzheimer’s changes, years before memory shifts. PET imaging, CSF biomarkers, and pulse pressure reveal two pathways: more plaque buildup and poorer brain clearance.

• cohorts of unimpaired adults across ALFA+, EPAD, and AMYPAD
• amyloid PET centiloids tied to higher SBP and PP at baseline
• longitudinal plaque accumulation linked to higher DBP
• CSF signature clarified by adjusting for Aβ40 to reflect clearance
• arterial stiffness and pulse pressure connecting to p‑tau in older adults
• two‑mechanism model: physical buildup and impaired fluid turnover
• practical frame for midlife hypertension control as brain protection
• limits of selected cohorts and implications for broader populations

Have that conversation with your doctor about your own numbers

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We trace a clear path from basal forebrain atrophy to cortical thinning and subtle cognitive decline, and show how amyloid acts as an amplifier in the preclinical stage of Alzheimer’s. The timeline and mechanisms point to practical biomarkers and earlier therapeutic targets.

• preclinical Alzheimer’s framed as a long silent phase 
• cholinergic basal forebrain as the cortex’s power grid 
• cortical thinning as the structural bridge to symptoms 
• cohort: 230 cognitively normal older adults, ~6 years 
• tools: MRI with FreeSurfer, PIB-PET, PACC5 composite 
• universal CBF decline, faster with amyloid positivity 
• significant cortical thinning in AD-relevant regions 
• cognitive decline concentrated in amyloid-positive group 
• mediation: ~44 percent of CBF effect via cortical thinning 
• remaining decline likely tied to tau, synapses, vasculature 
• amyloid as toxic amplifier of the CBF–cortex link 
• translational takeaways: combined biomarkers and trial stratification 
• early cholinergic support as a candidate intervention

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We test a bold idea: your baseline gray matter pattern can predict whether multidomain prevention actually protects your brain. By clustering MRI scans into six subtypes, we uncover who responds, who doesn’t, and how vascular risks tip the balance.

• global dementia risk and why prevention must scale
• strengths and limits of the FINGER multidomain model
• heterogeneity in gray matter masks average effects
• six MRI-derived structural subtypes with distinct thinning patterns
• vascular and demographic fingerprints across clusters
• diffuse and frontal thinning groups as top responders
• posterior thinning groups as structural nonresponders
• neuroplasticity, reserve, and ceiling effects as mechanisms
• tailoring prevention by brain subtype and risk profile
• replication needs across the worldwide FINGER network

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We trace the leap from single‑target antibodies that slow decline by about 30 percent to ambitious combination strategies that attack Alzheimer’s from multiple angles. Along the way we unpack drug‑device synergies, biomarker‑guided precision, smarter trials, and the hard question of affordability.

• proof of concept for anti‑amyloid efficacy and its ceiling
• rationale for multi‑target combinations beyond amyloid and tau
• add‑on layering versus purpose‑built novel combinations
• drug‑device approaches including focused ultrasound to open the BBB
• mechanism optimization for metabolism, tolerability and penetration
• integrated care with lifestyle, metabolic targets and quality oversight
• factorial and fast‑fail trial designs to test synergy efficiently
• biomarkers for target engagement and predictive selection
• platform trials to accelerate and streamline development
• access, cost and routes to democratize effective treatment

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We break down 12 randomized trials that layer lifestyle with targeted compounds to prevent or delay dementia. The data show where combinations help, where they fail, and why precision targeting and smarter trial designs matter for real-world brain health.

• Limits of antibody eligibility and why lifestyle leads
• Fourteen modifiable risk factors and the 45% prevention potential
• FINGER as the global template for multidomain change
• Who benefits: SCD, MCI, and prodromal AD populations
• Add-ons tested: omega-3s, vitamin D, Souvenaid, EGCG, metformin
• MAPT’s subgroup wins in amyloid-positive and high vascular risk groups
• SYNERGIC finding that vitamin D added no extra benefit
• Souvenaid plus lifestyle feasibility and adherence
• MET-FINGER’s precision prevention for APOE4 with metabolic risk
• PENSA’s delayed effects after washout and what it implies
• Heterogeneity problems and the need for factorial designs
• Biomarker breakthroughs enabling better recruitment and monitoring
• Toward layered, personalized, lifelong brain-health strategies

What is the one factor you could maybe focus on changing, even slightly, starting this week?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We dig into why single-target drugs fall short against Alzheimer’s and how explainable AI can design smarter, safer combination therapies that target upstream biology while managing risks like ARIA. We share tools, data sources, and a roadmap to validate predictions with digital twins and organoids.

• global burden and rising projections
• modest gains from new antibodies and unmet need
• failed and ongoing combo trials since 2015
• PK versus PD strategies and examples
• shift to endophenotypes and network medicine
• three design patterns for combinations
• copathologies, CAA, and managing ARIA
• AI toolkits: networks, knowledge graphs, QSP
• validation via real-world data and organoids
• roadblocks in data quality, regulation, and explainability

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We trace the move from silver bullets to synergy, showing why Alzheimer’s demands combination therapy that hits amyloid, tau, inflammation, and metabolism while pairing drugs with precise lifestyle changes. We explain how adaptive trials, repurposed medicines, and prevention strategies could push past today’s 30 percent ceiling.

• scale of aging demographics and the rising Alzheimer’s burden
• limits of symptom drugs and why plaque clearance alone falls short
• the 30 percent benefit of antibodies and the remaining gap
• rationale for combination therapy across multiple pathways
• GLP‑1 agonists, metformin, and drug repurposing logic
• senolytics and anti‑tau plus anti‑amyloid combinations
• adaptive trial designs integrating background antibody use
• funding challenges for off‑patent drugs and AI data needs
• pivot toward multimodal care and prevention strategies

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We explore why family and close friendships are not just nice-to-have but biological drivers of long life. From Blue Zones to the Harvard Study, we connect oxytocin, inflammation, purpose, and ritual into a practical blueprint for belonging.

• connection as a biological need that regulates stress and inflammation
• how bonds buffer cognitive decline and support brain health
• Blue Zones structures for proximity, ritual, and reciprocity
• moai in Okinawa and Sabbath in Loma Linda as social design
• honoring elders for purpose, dignity, and intergenerational benefit
• practical habits for busy, distant families
• chosen family as a legitimate longevity engine
• the Harvard Study’s finding on relationship quality
• a simple weekly challenge to show up consistently

Make that call you've been meaning to make. Plan that simple meal together. Schedule that protected half hour just to connect.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We dig into why belonging may extend life by four to fourteen years and how rituals, fellowship, and faith communities reduce stress and inflammation. Research, Blue Zone stories, and practical steps show how to build connection even in a busy, mobile world.

• Blue Zones share strong faith and social ties
• Consistent participation matters more than doctrine
• Stress reduction through prayer, music, and reflection
• Resilience from shared stories and support
• Biological effects on inflammation and immunity
• Loneliness linked to higher disease risk
• Practical steps to build community
• Rituals as weekly and daily health anchors

So here's the challenge for you this week, based on everything we've discussed. Reconnect with a ritual you already have, maybe one that slipped a bit, or create a new one. Join that group you've been thinking about, start that five-minute reflection habit, reach out and schedule regular time with someone important, show up for connection.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!